HOOK
Income statement / Annual
Last year (2024), HOOKIPA Pharma Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, HOOKIPA Pharma Inc.'s net income was -$43.50 M.
See HOOKIPA Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$20.13 M |
$14.25 M |
$18.45 M |
$19.58 M |
$11.94 M |
$7.63 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$3.55 M
|
$3.60 M
|
$4.64 M
|
$53.13 M
|
$46.31 M
|
$21.97 M
|
$398,000.00
|
| Gross Profit |
$0.00
|
$16.58 M
|
$10.65 M
|
$13.81 M
|
-$33.55 M
|
-$34.37 M
|
-$14.34 M
|
-$398,000.00
|
| Gross Profit Ratio |
0
|
0.82
|
0.75
|
0.75
|
-1.71
|
-2.88
|
-1.88
|
0
|
| Research and Development Expenses |
$68.51 M
|
$86.42 M
|
$68.65 M
|
$82.85 M
|
$54.79 M
|
$46.31 M
|
$21.97 M
|
$9.77 M
|
| General & Administrative Expenses |
$20.23 M
|
$18.63 M
|
$18.76 M
|
$17.27 M
|
$18.08 M
|
$16.72 M
|
$6.84 M
|
$4.39 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.23 M
|
$18.63 M
|
$18.76 M
|
$17.27 M
|
$18.08 M
|
$16.72 M
|
$6.84 M
|
$4.39 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$392,000.00
|
-$2.84 M
|
$3.07 M
|
$601,000.00
|
$133,000.00
|
-$25,000.00
|
| Operating Expenses |
$88.73 M
|
$117.82 M
|
$87.40 M
|
$100.12 M
|
$72.87 M
|
$63.03 M
|
$23.20 M
|
$12.09 M
|
| Cost And Expenses |
$0.00
|
$117.82 M
|
$87.40 M
|
$100.12 M
|
$72.87 M
|
$63.03 M
|
$23.20 M
|
$12.09 M
|
| Interest Income |
$3.70 M
|
$5.29 M
|
$8.24 M
|
$27,000.00
|
$9.20 M
|
$1.59 M
|
$0.00
|
$0.00
|
| Interest Expense |
-$2,000.00
|
$317,000.00
|
$687,000.00
|
$898,000.00
|
$786,000.00
|
$877,000.00
|
$778,000.00
|
$606,000.00
|
| Depreciation & Amortization |
$0.00
|
$3.55 M
|
$3.60 M
|
$4.64 M
|
$4.15 M
|
$3.07 M
|
$640,000.00
|
$398,000.00
|
| EBITDA |
-$51.46 M |
-$77.34 M |
-$60.40 M |
-$70.13 M |
-$39.15 M |
-$39.09 M |
-$14.80 M |
-$13.76 M |
| EBITDA Ratio |
0
|
-3.84
|
-5.13
|
-4.43
|
-2.72
|
-4.28
|
-1.94
|
0
|
| Operating Income Ratio |
0
|
-4.85
|
-5.13
|
-4.43
|
-2.72
|
-4.28
|
-2.78
|
0
|
| Total Other Income/Expenses Net |
$8.06 M
|
$16.48 M
|
$8.47 M
|
$6.01 M
|
$9.20 M
|
$8.05 M
|
$4.97 M
|
$1.44 M
|
| Income Before Tax |
-$43.40 M
|
-$81.21 M
|
-$64.92 M
|
-$75.67 M
|
-$44.08 M
|
-$43.04 M
|
-$16.21 M
|
-$12.72 M
|
| Income Before Tax Ratio |
0
|
-4.03
|
-4.56
|
-4.1
|
-2.25
|
-3.6
|
-2.13
|
0
|
| Income Tax Expense |
$106,000.00
|
$368,000.00
|
$230,000.00
|
$1,000.00
|
-$10.28 M
|
-$8.89 M
|
$24,000.00
|
$4,000.00
|
| Net Income |
-$43.50 M
|
-$81.58 M
|
-$64.92 M
|
-$75.67 M
|
-$44.08 M
|
-$43.04 M
|
-$16.24 M
|
-$12.72 M
|
| Net Income Ratio |
0
|
-4.05
|
-4.56
|
-4.1
|
-2.25
|
-3.6
|
-2.13
|
0
|
| EPS |
-3.47 |
-8.63 |
-9.91 |
-23.04 |
-16.93 |
-24.1 |
-177.58 |
-139.54 |
| EPS Diluted |
-3.47 |
-8.63 |
-9.91 |
-23.04 |
-16.93 |
-24.1 |
-177.57 |
-139.54 |
| Weighted Average Shares Out |
$12.54 M
|
$9.45 M
|
$6.55 M
|
$3.28 M
|
$2.60 M
|
$1.79 M
|
$91,437.00
|
$91,177.00
|
| Weighted Average Shares Out Diluted |
$12.54 M
|
$9.45 M
|
$6.55 M
|
$3.28 M
|
$2.60 M
|
$1.79 M
|
$91,438.00
|
$91,177.00
|
| Link |
|
|
|
|
|
|
|
|
